Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Retrotransposon Gag-like protein 8C (RTL8C) is a small, truncated protein derived from an ancestral retrotransposon gag gene and is a member of the Mart/RTL8 family of domesticated retroelement proteins[1]. RTL8C is highly homologous to PEG10 in the N-terminal capsid-like region but lacks a C-terminal domain typical of canonical retroelement Gag proteins. RTL8C interacts directly with PEG10, leading to decreased formation and extracellular release of PEG10-derived virus-like particles, possibly by interfering with capsid assembly. RTL8C also forms a tripartite regulatory node with PEG10 and the ubiquitin-binding protein UBQLN2, where RTL8C is required for UBQLN2-mediated degradation of PEG10. Although essential in PEG10 regulation and cellular stress granule dynamics, there is currently no evidence that RTL8C serves directly as a therapeutic target, nor are there known drugs or biomarker uses associated with this molecule[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Retrotransposon Gag-like protein 8C (RTL8C).